Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.350 +0.010 (+0.75%)
Official Closing Price Updated: 8:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
 
Via Benzinga
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts
 
Via Benzinga
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Issues Letter to Stockholders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics's Earnings Outlook
 
Via Benzinga
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 14, 2024
 
Via Benzinga
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at 2024 BIO International Convention
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Changes to Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.